Acrivon Therapeutics (ACRV) leaders receive new RSU and stock grants
Rhea-AI Filing Summary
Acrivon Therapeutics, Inc. reported equity awards to senior leaders in the form of restricted stock units (RSUs) and common stock grants coded as acquisitions. One award covers 72,706 RSUs at a grant price of $0.00 per share, and another covers 180,095 shares of Common Stock at $0.00 per share.
Each RSU represents a contingent right to receive one share of Common Stock. Of the RSUs, 16.67% are scheduled to vest on November 18, 2026, with the remaining units vesting in 10 substantially equal quarterly installments, subject to the executive’s continuous service. After these grants, one indirect holding totals 386,343 shares and one direct holding totals 2,259,046 shares, with certain shares held by each executive’s spouse and the non-holding spouse disclaiming beneficial ownership except for any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Blume-Jensen Peter, Masson Kristina
Role
President and CEO | EVP - Business Operations
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 180,095 | $0.00 | -- |
| Grant/Award | Common Stock | 72,706 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 2,259,046 shares (Direct);
Common Stock — 386,343 shares (Indirect, See Footnote)
Footnotes (1)
- These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Key Figures
RSUs granted: 72,706 units
Common shares granted: 180,095 shares
RSU vesting tranche: 16.67%
+4 more
7 metrics
RSUs granted
72,706 units
Restricted stock units granted on May 18, 2026
Common shares granted
180,095 shares
Common Stock grant on May 18, 2026
RSU vesting tranche
16.67%
Initial RSU vesting on November 18, 2026
Remaining RSU vesting schedule
10 quarterly installments
RSUs vest in substantially equal installments after initial vest
Indirect holdings after grant
386,343 shares
Total indirect Common Stock position following transaction
Direct holdings after grant
2,259,046 shares
Total direct Common Stock position following transaction
Grant price per share
$0.00/share
Price for both RSU and stock grants
Key Terms
restricted stock units ("RSUs"), contingent right, pecuniary interest, continuous service
4 terms
restricted stock units ("RSUs") financial
"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
contingent right financial
"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."
pecuniary interest financial
"Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."
continuous service financial
"in each case subject to the Reporting Person's continuous service through each such vesting date."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Acrivon Therapeutics (ACRV) report on this Form 4?
The Form 4 reports two equity grant transactions classified as acquisitions. One is a 72,706-unit restricted stock unit (RSU) award and the other is a 180,095-share Common Stock grant, both at a grant price of $0.00 per share to senior executives.
How many Acrivon Therapeutics (ACRV) RSUs were granted and how do they vest?
A total of 72,706 restricted stock units were granted to an executive. Each RSU equals one Acrivon common share. About 16.67% vest on November 18, 2026, with the remaining RSUs vesting in 10 substantially equal quarterly installments, subject to continuous service.
Do the ACRV executives have any conditions tied to these RSU awards?
Yes. The RSUs vest only if the reporting executive maintains continuous service through each vesting date. Initial vesting of 16.67% occurs on November 18, 2026, and the remaining units vest over 10 subsequent quarterly installments under the same service condition.
How is spousal ownership treated in this Acrivon Therapeutics (ACRV) Form 4?
Some securities are held by one spouse who is also an executive, while the other spouse is a reporting person. Each non-holding spouse disclaims beneficial ownership of the securities held by their partner, except to the extent of any pecuniary interest in those shares.